A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
A study for patients with select advanced cancers using study drug INCB24360
Sponsor: InCyte
Enrolling: Male and Female Patients
IRB Number: AAAO2406
U.S. Govt. ID: NCT02327078
Contact: Richard Carvajal MD: 646-248-1703 / rdc2150@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess how safe and well tolerated study drugs, INCB24360 and nivolumab, are given in combination in patients who have advanced or metastatic solid tumors. The study will also assess how well INCB24360 in combination with nivolumab works in preventing disease progression in patients with melanoma (MEL), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), ovarian cancer and diffuse large B cell lymphoma.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Do you have a confirmed diagnosis of NSCLC, MEL, CRC, SCCHN, or ovarian cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal MD
rdc2150@cumc.columbia.edu
646-248-1703
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE